ARDELYX, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is effective as of [—] by and between Ardelyx, Inc., a Delaware corporation (the “Company”), and «Indemnitee» (“Indemnitee”).
ARDELYX, INC. AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • California
This Amended and Restated Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Mark Kaufmann (the “Executive”) and Ardelyx, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”). This Agreement amends and restates in its entirety that certain Change in Control Severance Agreement by and between Executive and the Company effective as of August 16, 2011 (the “Prior Agreement”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • California
This Amended and Restated Executive Employment Agreement (the “Agreement”) is entered into as of June 6, 2014 (the “Effective Date”), by and between Michael Raab (“Executive”) and Ardelyx, Inc. (the “Company”).
Ardelyx, Inc. Shares Common Stock ($0.0001 par value) Underwriting AgreementUnderwriting Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations • New York
Ardelyx, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. Certain terms
Re: Employment AgreementEmployment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the position of Chief Business Officer, reporting to the Chief Executive Officer. This letter sets out the terms of your employment with the Company, which shall start the earlier of August 15, 2011.
Re: Employment AgreementEmployment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
On behalf of Ardelyx (the “Company”), I am pleased to offer you employment in the position of Vice President of Drug Development, reporting to the Chief Executive Officer. This letter sets out the terms of your employment with the Company which shall start on January 1, 2010.
Re: Employment AgreementEmployment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
On behalf of NteryX (the “Company”), I am pleased to offer you employment in the position of Vice President, Medicinal Chemistry, reporting to the Chief Technology Officer. This letter sets out the terms of your employment with the Company, which will be conditioned upon the occurrence of i) the closing of the Company’s Series A financing and ii) the approval by the Board of Directors, and shall start on the later of June 15, 2008 or the first Monday after the date of the Board meeting.
Re: Employment AgreementEmployment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
On behalf of NteryX (the “Company”), I am pleased to offer you employment in the position of Vice President, Finance and Operations, reporting initially to the Chief Technology Officer. This letter sets out the terms of your employment with the Company, which will be conditioned upon the occurrence of i) the closing of the Company’s Series A financing and ii) the approval by the Board of Directors, and shall start on the later of June 1, 2008 or the first Monday after the date of the Board meeting.
Re: Employment AgreementEmployment Agreement • June 9th, 2014 • Ardelyx, Inc. • Pharmaceutical preparations
On behalf of Ardelyx, Inc. (the “Company”), I am pleased to offer you employment in the position of Vice President, Legal, reporting to the Chief Executive Officer. This letter sets out the terms of your employment with the Company which shall start on December 1, 2012.
